Share
Stemina Biomarker Discovery, Inc. has developed two reliable human stem cell-based assays for developmental toxicity screening.
devTOX quickPredict rapidly predicts the developmental toxicity potential of test articles with 89% accuracy (79% sensitivity, 100% specificity), while devTOX Discovery identifies changes in secreted metabolites to help identify mechanisms of toxicity. Both are available using human embryonic stem (hES) and induced pluripotent stem (iPS) cells.
These assays are already used in the US Environmental Protection Agency’s (EPA) ToxCast initiative, and in industry during discovery and preclinical development programs for test articles intended for use as pharmaceuticals, agricultural or industrial chemicals, cosmetics, or consumer products. Use of the devTOX assays as a screening tool during early development can reduce the number of compounds that are taken forward into animal tests.
Stemina recognises that evaluating a test article in more than one alternative assay yields a more complete view of the test article’s developmental toxicity potential, so are looking for partners who offer complementary assays which could form part of a suite of assays with devTOX.
Stemina also hope to connect with potential customers to expand the use of their assays.
Visit the CRACK IT Solutions website to find out more and to contact the Solution provider.